Gendicine
Gendicine
Gendicine (pronounced: jen-di-seen) is a gene therapy product used in the treatment of certain types of cancer. It was the first gene therapy product to be approved for clinical use.
Etymology
The term "Gendicine" is a portmanteau of the words "gene" and "medicine", reflecting its function as a gene therapy product.
Definition
Gendicine is a recombinant adenovirus that carries a wild-type p53 gene. The p53 gene is a tumor suppressor gene that is often mutated in cancer cells. By introducing a healthy copy of the p53 gene into cancer cells, Gendicine can induce apoptosis, or programmed cell death, in the cancer cells.
Usage
Gendicine is primarily used in the treatment of head and neck squamous cell carcinoma (HNSCC). It is administered by direct injection into the tumor.
Related Terms
- Gene therapy
- Cancer
- Recombinant
- Adenovirus
- p53 gene
- Tumor suppressor gene
- Apoptosis
- Head and neck squamous cell carcinoma
See Also
External links
- Medical encyclopedia article on Gendicine
- Wikipedia's article - Gendicine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski